Clone Scan (G)

What is Clone Scan (A) test?

Clone Scan (A) is a longitudinal, allele-specific MRD assay that tracks the patient’s baseline clonotype(s) identified by Clone Detect using UMI barcoding and deep sequencing. Clone scan test is designed for ongoing monitoring after therapy milestones to quantify MRD with ultra-high sensitivity

Why consider Clone Scan (A) test?

• Enables early detection of molecular relapse and treatment resistance, often preceding clinical or biochemical progression.
• Supports risk-adapted decision-making by quantifying depth of response after induction, post-transplant, and during maintenance.

Who should get this Clone Scan (A) test?

• Patients with an established clonotype from Clone Detect who are in active treatment or surveillance (post‑induction, post‑ASCT, maintenance, or at suspected relapse).
• Clinicians seeking actionable MRD kinetics to inform escalation, de‑escalation, or change of therapy.

More Information about Clone Scan (A) test

Minimal residual disease (MRD) is the very small number of cancer cells that remain after treatment and are below the detection limits of standard tests, and its presence or absence is a powerful predictor of outcome in multiple myeloma. Modern assays such as next‑generation flow cytometry and next‑generation sequencing measure MRD in bone marrow with sensitivities, with sustained MRD negativity associated with longer progression‑free and overall survival across disease settings.  

OTHER NAMES: Longitudinal MRD assay, MRD clonotype identification, ClonoSeq, MRD monitoring